Search research articles
Contact Us
Filters
Showing results (41-50 of 47) with videos related to
Page
of 5
Sort By:
You have reached the last page of results.
This site can display upto 47 results.
Oncoimmunology
|
January 4, 2018
ATTACK, a novel bispecific T cell-recruiting antibody with trivalent EGFR binding and monovalent CD3 binding for cancer immunotherapy
Seandean Lykke Harwood, Ana Alvarez-Cienfuegos, Natalia Nuñez-Prado, et al.
Oncoimmunology
|
April 28, 2023
A PD-L1/EGFR bispecific antibody combines immune checkpoint blockade and direct anti-cancer action for an enhanced anti-tumor response
Laura Rubio-Pérez, Rodrigo Lázaro-Gorines, Seandean L Harwood, et al.
Biochemistry
|
March 11, 2021
Modeling Immunity with Rosetta: Methods for Antibody and Antigen Design
Clara T Schoeder, Samuel Schmitz, Jared Adolf-Bryfogle, et al.
Science (New York, N.Y.)
|
May 16, 2020
De novo protein design enables the precise induction of RSV-neutralizing antibodies
Fabian Sesterhenn, Che Yang, Jaume Bonet, et al.
Nature Communications
|
August 24, 2016
Crowdsourced assessment of common genetic contribution to predicting anti-TNF treatment response in rheumatoid arthritis
Solveig K Sieberts, Fan Zhu, Javier García-García, et al.
Nature Communications
|
October 11, 2016
Erratum: Crowdsourced assessment of common genetic contribution to predicting anti-TNF treatment response in rheumatoid arthritis
Solveig K Sieberts, Fan Zhu, Javier García-García, et al.
Nature Methods
|
June 3, 2020
Macromolecular modeling and design in Rosetta: recent methods and frameworks
Julia Koehler Leman, Brian D Weitzner, Steven M Lewis, et al.
Page
of 5
Search research articles
Search
Showing results (41-50 of 47) with videos related to
Sort By:
Page
of 5
You have reached the last page of results.
This site can display upto 47 results.
Oncoimmunology
|
January 4, 2018
ATTACK, a novel bispecific T cell-recruiting antibody with trivalent EGFR binding and monovalent CD3 binding for cancer immunotherapy
Seandean Lykke Harwood, Ana Alvarez-Cienfuegos, Natalia Nuñez-Prado, et al.
Oncoimmunology
|
April 28, 2023
A PD-L1/EGFR bispecific antibody combines immune checkpoint blockade and direct anti-cancer action for an enhanced anti-tumor response
Laura Rubio-Pérez, Rodrigo Lázaro-Gorines, Seandean L Harwood, et al.
Biochemistry
|
March 11, 2021
Modeling Immunity with Rosetta: Methods for Antibody and Antigen Design
Clara T Schoeder, Samuel Schmitz, Jared Adolf-Bryfogle, et al.
Science (New York, N.Y.)
|
May 16, 2020
De novo protein design enables the precise induction of RSV-neutralizing antibodies
Fabian Sesterhenn, Che Yang, Jaume Bonet, et al.
Nature Communications
|
August 24, 2016
Crowdsourced assessment of common genetic contribution to predicting anti-TNF treatment response in rheumatoid arthritis
Solveig K Sieberts, Fan Zhu, Javier García-García, et al.
Nature Communications
|
October 11, 2016
Erratum: Crowdsourced assessment of common genetic contribution to predicting anti-TNF treatment response in rheumatoid arthritis
Solveig K Sieberts, Fan Zhu, Javier García-García, et al.
Nature Methods
|
June 3, 2020
Macromolecular modeling and design in Rosetta: recent methods and frameworks
Julia Koehler Leman, Brian D Weitzner, Steven M Lewis, et al.
Page
of 5